280 related articles for article (PubMed ID: 38213150)
21. Biomaterials for chimeric antigen receptor T cell engineering.
Niu H; Zhao P; Sun W
Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403
[TBL] [Abstract][Full Text] [Related]
22. Future perspectives on engineered T cells for cancer.
Posey AD; Young RM; June CH
Trends Cancer; 2024 Jun; ():. PubMed ID: 38853073
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen receptor T cells applied to solid tumors.
Zhou Z; Tao C; Li J; Tang JC; Chan AS; Zhou Y
Front Immunol; 2022; 13():984864. PubMed ID: 36389701
[TBL] [Abstract][Full Text] [Related]
24. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
Front Immunol; 2022; 13():871661. PubMed ID: 35911706
[TBL] [Abstract][Full Text] [Related]
25. CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapy.
Cui Y; Luo M; Gu C; He Y; Yao Y; Li P
Biophys Rep; 2023 Oct; 9(5):279-297. PubMed ID: 38516299
[TBL] [Abstract][Full Text] [Related]
26. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
Huang J; Huang X; Huang J
Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
[TBL] [Abstract][Full Text] [Related]
27. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
28. Nanotechnology-based chimeric antigen receptor T-cell therapy in treating solid tumor.
Zuo YH; Zhao XP; Fan XX
Pharmacol Res; 2022 Oct; 184():106454. PubMed ID: 36115525
[TBL] [Abstract][Full Text] [Related]
29. Challenges and interventions of chimeric antigen receptor-T cell therapy in solid tumors.
Liu S; Zhang Y
Chin J Cancer Res; 2023 Jun; 35(3):239-244. PubMed ID: 37440824
[TBL] [Abstract][Full Text] [Related]
30. CAR-T cell therapy in melanoma: A future success story?
Simon B; Uslu U
Exp Dermatol; 2018 Dec; 27(12):1315-1321. PubMed ID: 30288790
[TBL] [Abstract][Full Text] [Related]
31. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
32. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
Front Immunol; 2022; 13():887471. PubMed ID: 35935930
[TBL] [Abstract][Full Text] [Related]
33. Nuclear Imaging of CAR T Immunotherapy to Solid Tumors: In Terms of Biodistribution, Viability, and Cytotoxic Effect.
Ren M; Yao B; Han B; Li C
Adv Biol (Weinh); 2023 Jun; 7(6):e2200293. PubMed ID: 36642820
[TBL] [Abstract][Full Text] [Related]
34. Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies.
Hull CM; Maher J
Expert Opin Drug Discov; 2021 Oct; 16(10):1105-1117. PubMed ID: 34038292
[No Abstract] [Full Text] [Related]
35. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
[TBL] [Abstract][Full Text] [Related]
36. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
37. Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects.
Qian S; Villarejo-Campos P; Guijo I; Hernández-Villafranca S; García-Olmo D; González-Soares S; Guadalajara H; Jiménez-Galanes S; Qian C
Front Immunol; 2022; 13():841425. PubMed ID: 35401510
[TBL] [Abstract][Full Text] [Related]
38. The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.
Daei Sorkhabi A; Mohamed Khosroshahi L; Sarkesh A; Mardi A; Aghebati-Maleki A; Aghebati-Maleki L; Baradaran B
Front Immunol; 2023; 14():1113882. PubMed ID: 37020537
[TBL] [Abstract][Full Text] [Related]
39. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
[TBL] [Abstract][Full Text] [Related]
40. CAR T-Cell Therapy in Children with Solid Tumors.
Kulczycka M; Derlatka K; Tasior J; Lejman M; Zawitkowska J
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
